|
| | |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
| FORM 8-K |
| CURRENT REPORT |
| Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
| | | |
Date of Report (Date of earliest event reported): December 16, 2019 |
| | | |
| AMERICAN NATIONAL BANKSHARES INC. |
| (Exact name of registrant as specified in its charter) |
| | | |
| Virginia | 0-12820 | 54-1284688 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| | | |
Registrant’s telephone number, including area code: 434-792-5111 |
| | | |
| Not Applicable |
| (Former name or former address, if changed since last report.) |
|
| | |
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) | |
Securities registered pursuant to Section 12(b) of the Act:
|
| | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $1.00 par value | AMNB | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 16, 2019, Dr. Franklin W. Maddux, a member of the Boards of Directors of American National Bankshares Inc. (the “Company”) and its banking subsidiary, American National Bank and Trust Company (the “Bank”) since 2002, notified the Company and the Bank of his decision to resign as a director of both entities effective December 31, 2019.
Dr. Maddux has been named to the Management Board of Fresenius Medical Care, a leading provider of dialysis products and services and at which he is Global Chief Medical Officer. He will take on his new responsibilities at Fresenius Medical Care on January 1, 2020 and will not be in a position to continue his service as a director of the Company and the Bank. Dr. Maddux’s resignation is not due to any disagreement with the Company on any matter relating to its operations, policies or practices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | |
| | | | American National Bankshares Inc. |
| | | | (Registrant) |
| | | | |
| Date: | December 30, 2019 | By: | /s/ Jeffrey W. Farrar |
| | | | Jeffrey W. Farrar |
| | | | Executive Vice President, |
| | | | Chief Financial Officer, and Chief Operating Officer |
